Predictive biomarkers in colorectal carcinoma, such as mismatch repair (MMR) status and the mutational tumor profile—including BRAF, KRAS, NRAS, TP53, PIK3CA, and other mutations—carry biological and therapeutic significance. This evidence concerns the gene NRAS and neoplasm.